Therapeutic angiogenesis: potential role of basic fibroblast growth factor in patients with severe ischaemic heart disease.
Therapeutic angiogenesis is a rapidly evolving approach to the treatment of advanced coronary disease. The availability of growth factors such as basic fibroblast growth factor (bFGF or FGF2) has made possible the practical clinical application of this research. In this article, we summarise the basic biology of bFGF, a prototypical angiogenic growth factor, and the preclinical studies with this growth factor, and analyse recent clinical experience. While much remains to be learned, bFGF has been clearly shown to induce effective growth of new vasculature in a variety of animal models. The initial clinical data are promising, with patients demonstrating improvement in symptoms, quality of life and exercise tolerance. At the same time, the adverse effects profile has, to date, remained relatively benign.
Angiogenesis Research Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA. msimons@caregroup.harvard.edu
M
M
Simons
R J
RJ
Laham
M
M
Post
F W
FW
Sellke